LLR APC Meeting Minutes June 2024(905 KB) - LMSG/LLR APC minutes
Date added: 4th Jul 2024
| Drug Name | Classification | Clinical Indication | Comments |
|---|---|---|---|
| 1mg Estradiol and 100mg Micronised progesterone(Bijuve) | Green | Continuous combined hormone replacement therapy (HRT) for estrogen deficiency symptoms in postmenopausal women | |
| ABROCITINIB (Cibinqo ®) | Red | Treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy | |
| ACETYLCYSTEINE EFFERVESCENT TABLETS | Green | COPD Reduction of sputum viscosity |
LMSG Mucolytic prescribing guide Effervescent tablets only, prescribe generically. Capsules not to be prescribed. |
| Advagraf Prolonged Release (Tacrolimus) | Red | immunosuppression | |
| Atogepant (NEW) | Yellow | preventing migraine |
For preventing migraines |
| Beclometasone extra-fine/ Formoterol Inhaler (LUFORBEC pMDI) (NEW) | Green | Asthma and COPD |
Asthma: 100/6 mcg/dose and 200/6 mcg/dose COPD: 100/6 mcg/dose only |
| Cefepime dihydrochloride monohydrate/Enmetazobactam) powder for concentrate for solution for infusion (2 g/0.5 g) Exblifep | Grey | Complicated UTIs including pyelonephritis, hospital-acquired pneumonia, and treatment of bacteraemia in association (or potentially linked) with these infections | |
| Cytisine 1.5mg Tablets (NEW) | Red | For smoking cessation |
*25 day course only In case of treatment failure, the treatment should be discontinued and may be resumed after 2 to 3 months |
| DENOSUMAB 120mg (Xgeva®) (UPDATED) | Red | Prevention of skeletal related events for myeloma patients with CKD (GFR <10ml/min) | |
| DexcomONE plus | Yellow | Diabetes glucose monitoring for those included on the LLRAPC position statement | |
| FLUOCINOLONE ACETONIDE (Synalar®) | Green | Inflammatory skin disorders |
Synalar 0.00625% or 0.025% strength Available as gel, cream and ointment. |
| Freestyle Libre 2+ | Yellow |
Diabetes glucose monitoring for those included on the LLRAPC position statement. (updated software and sensor; plan to discontinue Freestyle Libre 2 over the next 12 months – July 2023 to July 2024) |
|
| ICOSAPENT ETHYL (Vazkepa ®) (UPDATED) | Green | Raised triglycerides in patients with CVD | |
| IVERMECTIN TABLETS (NEW) | Yellow | Gastrointestinal strongyloidiasis (anguillulosis) and suspected or diagnosed microfilaraemia | |
| IVERMECTIN TABLETS (NEW) | Green | Human sarcoptic scabies | |
| Patiromer (Veltassa) | Red | Hyperkalaemia | |
| Quinidine | Red | KCNT1 gene mutation related Early Infantile epileptic encephalopathy | |
| QUOFENIX | Red | Antibiotic | |
| Rekambys (Rilpivirine) | Red | Stable HIV infection | |
| Remdesivir and Tixagevimab Plus Cilgavimab | Red | for treating COVID-19 | |
| Rifapentine | Red | Treatment of latent tuberculosis, especially in patients with social exclusion and at high risk of noncompletion, or those with preexisting liver disease | |
| Rifaximin | Red | small intestinal bacterial overgrowth | |
| Rilecitinib (NEW) | Red |
50 mg once daily, consider discontinuation of treatment if no response after 36 weeks. A patient card should be provided. NICE TA 958 The manufacturer of Litfulo® has provided a Prescriber Guide, which includes a prescriber checklist. |
|
| SIALANAR | Yellow | Drooling in chronic neurological disorders | |
| TACROLIMUS Ointment | Green | Dermatitis |
Protopic 0.03% and 0.1% ointment |
| VEDOLIZUMAB (Entyvio®) | Red | Moderate to severe active UC or Crohn’s disease |
Devices: pen, pre-filled syringe or solution for infusion |
| Verkazia (Ciclosporin) eye drops | Yellow | Treatment of severe vernal keratoconjunctivitis (VKC) in children from 4 years of age and adolescence | |
| Visuxl | Green | Visuxl is indicated for the treatment of dry eye and corneal healingpost surgery |
Sodium hyaluronate |
| VOCABRIA | Red | Stable HIV infection |
Cabotegravir (Vocabria) |
| Voxelotor | Red | Reducing need for transfusion in sickle cell disease |
Oxbryta 500 mg film-coated tablets |
| Xonvea | Do not prescribe | nausea , vomiting in pregancy |
(Doxylamine & pyridoxine) |
| Zalkya | Green | Medical treatment of endometriosis |
Dienogest (Zalkya) |
Other Updates on this Website
Recent documents from LLR APC and TAS
LLRAPC Newsletter – May and June 2024(659 KB) - LMSG/LLR APC newsletters
Date added: 3rd Jul 2024
Chronic Insomnia Pathway(106 KB) - Guidelines
Date added: 28th Jun 2024
Wound Care Formulary Comparison Chart(770 KB) - Guidelines
Wound Care Formulary Comparison Chart updated July 24 Primary Care and LPT only
Date added: 20th Jun 2019
Asthma – Adult Guidelines(1,022 KB) - Guidelines
Uploaded June 2024
Date added: 16th May 2019
About the Leicester, Leicestershire and Rutland Area Prescribing Committee
In common with other local health communities, the Leicester, Leicestershire and Rutland Area Prescribing Committee (LLR APC) acknowledges the benefits of having a Leicestershire Health Community-wide strategy for the prescribing of specialist medicines and the managed entry of new drugs and related technologies.
Leicestershire Health Community comprises the Leicester, Leicestershire and Rutland Integrated Care Board, University Hospitals of Leicester (UHL) NHS Trust and Leicestershire Partnership NHS Trust (LPT), amongst which there is a total consensus on the need for this strategy, and the LLR APC has been in place since 2005. Learn more